Search

Your search keyword '"Wenzl, Heimo"' showing total 44 results
Start Over Author "Wenzl, Heimo"
44 results on '"Wenzl, Heimo"'

3. Diagnostic delay in patients with inflammatory bowel disease in Austria

Author

Novacek, Gottfried, Gröchenig, Hans Peter, Haas, Thomas, Wenzl, Heimo, Steiner, Pius, Koch, Robert, Feichtenschlager, Thomas, Eckhardt, Gerald, Mayer, Andreas, Kirchgatterer, Andreas, Ludwiczek, Othmar, Platzer, Reingard, Papay, Pavol, Gartner, Johanna, Fuchssteiner, Harry, Miehsler, Wolfgang, Peters, Paul-Gerhard, Reicht, Gerhard, Vogelsang, Harald, Dejaco, Clemens, Waldhör, Thomas, and Austrian IBD Study Group (ATISG)

Published
2019
Full Text
View/download PDF

5. Factors Associated with Response to Systemic Corticosteroids in Active Ulcerative Colitis: Results from a Prospective, Multicenter Trial

Author

Blesl, Andreas, primary, Borenich, Andrea, additional, Gröchenig, Hans Peter, additional, Novacek, Gottfried, additional, Primas, Christian, additional, Reinisch, Walter, additional, Kutschera, Maximilian, additional, Illiasch, Constanze, additional, Hennlich, Barbara, additional, Steiner, Pius, additional, Koch, Robert, additional, Tillinger, Wolfgang, additional, Haas, Thomas, additional, Reicht, Gerhard, additional, Mayer, Andreas, additional, Ludwiczek, Othmar, additional, Miehsler, Wolfgang, additional, Steidl, Karin, additional, Binder, Lukas, additional, Baumann-Durchschein, Franziska, additional, Fürst, Stefan, additional, Reider, Simon, additional, Watschinger, Christina, additional, Wenzl, Heimo, additional, Moschen, Alexander, additional, Berghold, Andrea, additional, and Högenauer, Christoph, additional

Published
2023
Full Text
View/download PDF

6. Prevalence and indicators of use of complementary and alternative medicine in Austrian patients with inflammatory bowel disease

Author

Gröchenig, Hans Peter, Waldhör, Thomas, Haas, Thomas, Wenzl, Heimo, Steiner, Pius, Koch, Robert, Feichtenschlager, Thomas, Eckhardt, Gerald, Mayer, Andreas, Kirchgatterer, Andreas, Ludwiczek, Othmar, Platzer, Reingard, Papay, Pavol, Gartner, Johanna, Fuchssteiner, Harry, Miehsler, Wolfgang, Peters, Paul-Gerhard, Reicht, Gerhard, Kutschera, Maximilian, Dejaco, Clemens, Vogelsang, Harald, and Novacek, Gottfried

Published
2019
Full Text
View/download PDF

14. Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study

Author

Blesl, Andreas, primary, Binder, Lukas, additional, Högenauer, Christoph, additional, Wenzl, Heimo, additional, Borenich, Andrea, additional, Pregartner, Gudrun, additional, Berghold, Andrea, additional, Mestel, Sigrid, additional, Kump, Patrizia, additional, Baumann‐Durchschein, Franziska, additional, and Petritsch, Wolfgang, additional

Published
2021
Full Text
View/download PDF

18. sj-pdf-1-ueg-10.1177_2050640620946874 - Supplemental material for Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease

Author

Kutschera, Maximilian, Waldhör, Thomas, Gröchenig, Hans Peter, Haas, Thomas, Wenzl, Heimo, Steiner, Pius, Koch, Robert, Feichtenschlager, Thomas, Eckhardt, Gerald, Mayer, Andreas, Kirchgatterer, Andreas, Ludwiczek, Othmar, Platzer, Reingard, Papay, Pavol, Gartner, Johanna, Fuchssteiner, Harry, Paul-Gerhard Peters, Reicht, Gerhard, Moser, Gabriele, Dejaco, Clemens, Vogelsang, Harald, Primas, Christian, Novacek, Gottfried, and Miehsler, Wolfgang

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 110308 Geriatrics and Gerontology, 69999 Biological Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620946874 for Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease by Maximilian Kutschera, Thomas Waldhör, Hans Peter Gröchenig, Thomas Haas, Heimo Wenzl, Pius Steiner, Robert Koch, Thomas Feichtenschlager, Gerald Eckhardt, Andreas Mayer, Andreas Kirchgatterer, Othmar Ludwiczek, Reingard Platzer, Pavol Papay, Johanna Gartner, Harry Fuchssteiner, Paul-Gerhard Peters, Gerhard Reicht, Gabriele Moser, Clemens Dejaco, Harald Vogelsang, Christian Primas, Gottfried Novacek and Wolfgang Miehsler in United European Gastroenterology Journal

Published
2020
Full Text
View/download PDF

23. Successful Pregnancies After Regression of AA Amyloidosis by Anti-inflammatory Therapy in Chronic Active Crohn's Disease.

Author

Blesl, Andreas, Rainer, Florian, Pollheimer, Marion, Kump, Patrizia, Durchschein, Franziska, Wenzl, Heimo, Eller, Kathrin, Krisper, Peter, Petritsch, Wolfgang, and Högenauer, Christoph

Subjects
CROHN'S disease, AMYLOIDOSIS, CARDIAC amyloidosis, INFLAMMATORY bowel diseases, ENTERITIS, DISEASE remission, AMYLOIDOSIS diagnosis, CROHN'S disease diagnosis, ANTI-inflammatory agents, COMBINATION drug therapy, TREATMENT effectiveness, PREGNANCY outcomes, DISEASE complications
Published
2020
Full Text
View/download PDF

24. Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

Author

Miehsler, Wolfgang, additional, Dejaco, Clemens, additional, Gröchenig, Hans-Peter, additional, Fuchssteiner, Harry, additional, Högenauer, Christoph, additional, Kazemi-Shirazi, Lili, additional, Maier, Harald, additional, Mayer, Andreas, additional, Moschen, Alexander, additional, Reinisch, Walter, additional, Petritsch, Wolfgang, additional, Platzer, Reingard, additional, Steiner, Pius, additional, Tilg, Herbert, additional, Vogelsang, Harald, additional, Wenzl, Heimo, additional, and Novacek, Gottfried, additional

Published
2018
Full Text
View/download PDF

25. Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease

Author

Kutschera, Maximilian, Waldhör, Thomas, Gröchenig, Hans Peter, Haas, Thomas, Wenzl, Heimo, Steiner, Pius, Koch, Robert, Feichtenschlager, Thomas, Eckhardt, Gerald, Mayer, Andreas, Kirchgatterer, Andreas, Ludwiczek, Othmar, Platzer, Reingard, Papay, Pavol, Gartner, Johanna, Fuchssteiner, Harry, Peters, Paul‐Gerhard, Reicht, Gerhard, Moser, Gabriele, Dejaco, Clemens, Vogelsang, Harald, Primas, Christian, Novacek, Gottfried, and Miehsler, Wolfgang

Abstract

Patients with inflammatory bowel disease (IBD) suffer from various symptoms, impairing their quality of life and often affecting psychosocial issues. This may lead to the need for additional psychological care. This study investigated patients' subjective need for integrated psychosomatic support and psychotherapy and indicators for it. This is a cross‐sectional multicentre study in Austrian IBD patients who were in routine care at 18 IBD outpatient clinics. Patients filled in an anonymous, validated questionnaire (Assessment of the Demand for Additional Psychological Treatment Questionnaire [ADAPT]) assessing the need for psychological care. The ADAPT gives two separate scores: the need for integrated psychosomatic support and for psychotherapy. In addition, health‐related quality of life and the use of complementary and alternative medicine as well as clinical and socio‐demographic variables were queried. Multivariable regression analysis was performed to estimate the effect of the previously mentioned variables on the need for additional psychological care. Of 1286 patients, 29.7% expressed a need for additional psychological care, 19.6% expressed a need for integrated psychosomatic support and 20.2% expressed a need for psychotherapy. In the multivariable analysis, the two strongest indicators for the need for both types of psychological care were the use of complementary and alternative medicine (for integrated psychosomatic support: odds ratio = 1.64, 95% confidence interval 1.13–2.39, p= 0.010; for psychotherapy: odds ratio = 1.74, 95% confidence interval 1.20–2.53, p= 0.004), and a low health‐related quality of life score (for integrated psychosomatic support: odds ratio = 0.95, 95% confidence interval 0.94–0.96, p< 0.001; for psychotherapy: odds ratio = 0.96, 95% confidence interval 0.94–0.97, p< 0.001). About 30% of the Austrian IBD patients expressed a need for integrated psychosomatic support and/or psychotherapy. The most important indicators for this need were the use of complementary and alternative medicine and low quality of life. What is already known? Despite ongoing improvement of treatment options, patients may not respond to treatment or may develop side effects. Due to this burden of disease, patients may also suffer from psychological symptoms, such as depressionIn our previous study in 2008, we found that 31% of patients with inflammatory bowel disease (IBD) expressed a subjective need for psychological interventions Despite ongoing improvement of treatment options, patients may not respond to treatment or may develop side effects. Due to this burden of disease, patients may also suffer from psychological symptoms, such as depression In our previous study in 2008, we found that 31% of patients with inflammatory bowel disease (IBD) expressed a subjective need for psychological interventions What are the significant and/or new findings of the study? Despite improvements in therapy, around 30% of patients with IBD express a subjective need for psychological interventionsThis subjective need for psychological interventions is associated with complementary and alternative medicine use and low quality of life Despite improvements in therapy, around 30% of patients with IBD express a subjective need for psychological interventions This subjective need for psychological interventions is associated with complementary and alternative medicine use and low quality of life

Published
2021
Full Text
View/download PDF

28. Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronischentzündlichen Darmerkrankungen.

Author

Miehsler, Wolfgang, Dejaco, Clemens, Gröchenig, Hans-Peter, Fuchssteiner, Harry, Högenauer, Christoph, Kazemi-Shirazi, Lili, Maier, Harald, Mayer, Andreas, Moschen, Alexander, Reinisch, Walter, Petritsch, Wolfgang, Platzer, Reingard, Steiner, Pius, Tilg, Herbert, Vogelsang, Harald, Wenzl, Heimo, and Novacek, Gottfried

Published
2018
Full Text
View/download PDF

29. Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease

Author

Kutschera, Maximilian, Waldhör, Thomas, Gröchenig, Hans Peter, Haas, Thomas, Wenzl, Heimo, Steiner, Pius, Koch, Robert, Feichtenschlager, Thomas, Eckhardt, Gerald, Mayer, Andreas, Kirchgatterer, Andreas, Ludwiczek, Othmar, Platzer, Reingard, Papay, Pavol, Gartner, Johanna, Fuchssteiner, Harry, Peters, Paul-Gerhard, Reicht, Gerhard, Moser, Gabriele, Dejaco, Clemens, Vogelsang, Harald, Primas, Christian, Novacek, Gottfried, and Miehsler, Wolfgang

Abstract

Introduction Patients with inflammatory bowel disease suffer from various symptoms, impairing their quality of life and often affecting psychosocial issues. This may lead to the need for additional psychological care. This study investigated patients’ subjective need for integrated psychosomatic support and psychotherapy and indicators for it.Materials and methods This is a cross-sectional multicentre study in Austrian inflammatory bowel disease patients who were in routine care at 18 inflammatory bowel disease outpatient clinics. Patients filled in an anonymous, validated questionnaire (Assessment of the Demand for Additional Psychological Treatment Questionnaire, ADAPT) assessing the need for psychological care. The Assessment of the Demand for Additional Psychological Treatment Questionnaire gives two separate scores: the need for integrated psychosomatic support and for psychotherapy. In addition, health-related quality of life and the use of complementary and alternative medicine as well as clinical and sociodemographic variables were queried. Multivariable regression analysis was performed to estimate the effect of the previously mentioned variables on the need for additional psychological care.Results Of 1286 patients, 29.7% expressed a need for additional psychological care, 19.6% expressed a need for integrated psychosomatic support and 20.2% expressed a need for psychotherapy. In the multivariable analysis, the two strongest indicators for the need for both types of psychological care were the use of complementary and alternative medicine (for integrated psychosomatic support: odds ratio?=?1.64, 95% confidence interval 1.13–2.39, p?=?0.010; for psychotherapy: odds ratio?=?1.74, 95% confidence interval 1.20–2.53, p?=?0.004), and a low health-related quality of life score (for integrated psychosomatic support: odds ratio?=?0.95, 95% confidence interval 0.94–0.96, p?

Published
2024
Full Text
View/download PDF

30. Opposing Roles of Prostaglandin D2 Receptors in Ulcerative Colitis

Author

Sturm, Eva M., primary, Radnai, Balazs, additional, Jandl, Katharina, additional, Stančić, Angela, additional, Parzmair, Gerald P., additional, Högenauer, Christoph, additional, Kump, Patrizia, additional, Wenzl, Heimo, additional, Petritsch, Wolfgang, additional, Pieber, Thomas R., additional, Schuligoi, Rufina, additional, Marsche, Gunther, additional, Ferreirós, Nerea, additional, Heinemann, Akos, additional, and Schicho, Rudolf, additional

Published
2014
Full Text
View/download PDF

31. Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis

Author

Kump, Patrizia K., primary, Gröchenig, Hans-Peter, additional, Lackner, Stefan, additional, Trajanoski, Slave, additional, Reicht, Gerhard, additional, Hoffmann, K. Martin, additional, Deutschmann, Andrea, additional, Wenzl, Heimo H., additional, Petritsch, Wolfgang, additional, Krejs, Guenter J., additional, Gorkiewicz, Gregor, additional, and Högenauer, Christoph, additional

Published
2013
Full Text
View/download PDF

42. Is Gastroparesis in Diabetes Cured by Gastrectomy?

Author

Schnedi, Wolfgang J., Wenzl, Heimo H., Obermayer-Pietsch, Barbara, Roller, Regina E., and Lipp, Rainer W.

Subjects
*GASTRECTOMY, *DISEASE risk factors, *DIABETES
Abstract

Comments on the study conducted by Bell et al which reported that gastroparesis in diabetes is cured by gastrectomy. Risk factors for the development of autonomic neuropathy with gastroparesis in a diabetic patient; Symptoms of gastric carcinoids.

Published
1999

43. Opposing Roles of Prostaglandin D2 Receptors in Ulcerative Colitis.

Author

Sturm, Eva M., Radnai, Balazs, Jandl, Katharina, Stančić, Angela, Parzmair, Gerald P., Högenauer, Christoph, Kump, Patrizia, Wenzl, Heimo, Petritsch, Wolfgang, Pieber, Thomas R., Schuligoi, Rufina, Marsche, Gunther, Ferreirós, Nerea, Heinemann, Akos, and Schicho, Rudolf

Subjects
*PROSTAGLANDIN receptors, *ULCERATIVE colitis, *IMMUNOHISTOCHEMISTRY, *LEUCOCYTES, *T cells
Abstract

Proresolution functions were reported for PGD2 in colitis, but the role of its two receptors, D-type prostanoid (DP) and, in particular, chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2), is less well defined. We investigated DP and CRTH2 expression and function during human and murine ulcerative colitis (UC). Expression of receptors was measured by flow cytometry on peripheral blood leukocytes and by immunohistochemistry and immunoblotting in colon biopsies of patients with active UC and healthy individuals. Receptor involvement in UC was evaluated in a mouse model of dextran sulfate sodium colitis. DP and CRTH2 expression changed in leukocytes of patients with active UC in a differential manner. In UC patients, DP showed higher expression in neutrophils but lower in monocytes as compared with control subjects. In contrast, CRTH2 was decreased in eosinophils, NK, and CD3+ T cells but not in monocytes and CD3+/CD4+ T cells. The decrease of CRTH2 on blood eosinophils clearly correlated with disease activity. DP correlated positively with disease activity in eosinophils but inversely in neutrophils. CRTH2 internalized upon treatment with PGD2 and 11-dehydro TXB2 in eosinophils of controls. Biopsies of UC patients revealed an increase of CRTH2-positive cells in the colonic mucosa and high CRTH2 protein content. The CRTH2 antagonist CAY10595 improved, whereas the DP antagonist MK0524 worsened inflammation in murine colitis. DP and CRTH2 play differential roles in UC. Although expression of CRTH2 on blood leukocytes is downregulated in UC, CRTH2 is present in colon tissue, where it may contribute to inflammation, whereas DP most likely promotes anti-inflammatory actions. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

44. [Second Austrian consensus on the safe use of anti-TNFα-antibodies in patients with inflammatory bowel diseases].

Author

Miehsler W, Dejaco C, Gröchenig HP, Fuchssteiner H, Högenauer C, Kazemi-Shirazi L, Maier H, Mayer A, Moschen A, Reinisch W, Petritsch W, Platzer R, Steiner P, Tilg H, Vogelsang H, Wenzl H, and Novacek G

Subjects
Austria, Consensus, Female, Humans, Inflammatory Bowel Diseases virology, Pregnancy, Tumor Necrosis Factor-alpha immunology, Antibodies, Monoclonal therapeutic use, Gastrointestinal Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Infliximab therapeutic use, Tumor Necrosis Factor-alpha antagonists & inhibitors
Abstract

Anti-TNFα-antibodies have revolutionized the therapy of inflammatory bowel diseases and other immune-mediated inflammatory diseases. Due to the increasing application of these substances, the Working Group of Inflammatory Bowel Diseases of the Austrian Association of Gastroenterology and Hepatology intended to update their consensus report on the safe use of Infliximab (published in 2010) and to enlarge its scope to cover all anti-TNFα-antibodies. The present consensus report summarizes the current evidence on the safe use of anti-TNFα-antibodies and covers the following topics: general risk of infection, bacterial infections (i. e., Clostridium difficile, Tuberculosis, food hygiene), Pneumocystis jiroveci, viral infections (i. e., Hepatitis B, Hepatitis C, HIV, CMV, VZV), vaccination in general and recommendation for vaccines, gastrointestinal aspects (i. e., perianal fistula, abdominal fistula, intestinal strictures, stenosis and bowel obstruction), dermatologic aspects (skin malignancies, eczema-like drug-related skin eruption), infusion reactions and immunogenicity, demyelinating diseases, hepatotoxicity, haematotoxicity, congestive heart failure, risk and history of malignancies, and pregnancy and breast feeding. For practical reasons, the relevant aspects are summarized in a checklist which is divided into two parts: issues to be addressed before therapy and issues to be addressed during therapy., Competing Interests: Wolfgang Miehsler: Vortrags- bzw. Beraterhonorare von MSD, AbbVie, Janssen und TakedaClemens Dejaco: Vortrags- und Beraterhonorare von MSD, AbbVie, Takeda, Astro-Pharma, Pfizer, JansenHans-Peter Gröchenig: Vortrags- und Beraterhonorare von Abbvie, MSD und Astro Pharma.Harry Fuchssteiner: Vortragshonorare von AbbVie und TakedaChristoph Högenauer: Vortrags- bzw. Beraterhonorare von MSD, Abbvie, Janssen, Takeda, Pfizer, Astro PharmaLili Kazemi-Shirazi: Vortragshonorare von MSD, AbbVie, Ferring, MerckSerono/Dr. Falk, Chiesi, Novartis, Roche, Phadia Austria/Thermo Fisher Scientific und CSL-Behring. Nicht finanzielle Unterstützung von Mylan, Abbott, MSD, Gilead, MerckSerono/Dr Falk und Novartis.Harald Maier: Vortragshonorare von AbbVieAndreas Mayer: Vortrags- bzw. Beraterhonorare von MSD, AbbVie, Pfizer, Astropharma, Takeda, JanssenAlexander Moschen: Vortrags- und Beraterhonorare von MSD, AbbVie, Pfizer, Astropharma, Takeda, JanssenWalter Reinisch: Vortrags- und Beraterhonorare von MSD, Abbvie, Pfizer, Astropharma, Celltrion, Amgen, Sandoz und Boehringer IngelheimWolfgang Petritsch: Vortrags- und Beraterhonorare von MSD, AbbVie, Astropharma, Jansen und TakedaReingard Platzer: Vortragshonorare von MSD, AbbVie und TakedaPius Steiner: Vortrags- bzw. Beraterhonorare von MSD, Abbie, Astropharma, Takeda und JanssenHerbert Tilg: Vorttragshonorare von Abbvie, MSD und TakedaHarald Vogelsang: Vortrags- und Beraterhonorare von MSD, AbbVie, Pfizer, Astropharma, Falk, Janssen, TakedaHeimo Wenzl: Vortrags- bzw. Beraterhonorare von MSD, Abbvie, Janssen, TakedaGottfried Novacek: Vortrags- und Beraterhonorare von MSD, AbbVie, Takeda, Pfizer, Janssen, (© Georg Thieme Verlag KG Stuttgart · New York.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results